Connecticut is currently home to 1249 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
NCT05786066
Recruiting
The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
12/19/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
Register for Updates
Genomic Predictors of Recurrent Pregnancy Loss
NCT05444283
Recruiting
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/19/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Recurrent Pregnancy Loss
Register for Updates
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT03493425
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
NCT03850574
Recruiting
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
Register for Updates
National Adaptive Trial for PTSD Related Insomnia
NCT03668041
Recruiting
Many Veterans with posttraumatic stress disorder (PTSD) have trouble sleeping or have frequent nightmares. So far, no medication has been approved for treatment of insomnia in PTSD. The purpose of this research study is to find out if taking medications called trazodone or eszopiclone can help decrease symptoms of insomnia in patients with PTSD. PTSD is a form of intense anxiety which sometimes results from severe trauma. Symptoms may include nightmares, flashbacks, troublesome memories, difficu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/18/2024
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Insomnia
Register for Updates
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
NCT05343572
Recruiting
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
12/17/2024
Locations: Yale Fertility Center, Orange, Connecticut
Conditions: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Register for Updates
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
NCT05838521
Recruiting
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Cervical Cancer
Register for Updates
TRUsted rEsidents and Housing Assistance to Decrease Violence Exposure in New Haven
NCT05723614
Recruiting
The overall objective of this study is to implement and test a strengths-based, community-driven intervention to reduce gun violence by (1) improving housing stability through providing financial assistance coupled with comprehensive financial education for the re-entry population as well as their family members, and (2) fostering greater support for mental health by training a trusted network of community members in trauma-informed counseling.
Gender:
ALL
Ages:
All
Trial Updated:
12/16/2024
Locations: Beaver Hills, New Haven, Connecticut
Conditions: Firearm Injury
Register for Updates
Effects of Acute and Chronic Empagliflozin Heart Failure
NCT05553938
Recruiting
This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Heart Failure
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Hartford Healthcare Cancer Institute at Hartford Hospital, Hartford, Connecticut
Conditions: Cervical Cancer
Register for Updates
VIBRANT: VIB4920 for Active Lupus Nephritis
NCT05201469
Recruiting
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Yale University School of Medicine: Section of Rheumatology, New Haven, Connecticut
Conditions: Lupus Nephritis
Register for Updates